Pluri (PLUR) Competitors $5.01 -0.07 (-1.38%) Closing price 07/15/2025 03:54 PM EasternExtended Trading$5.14 +0.13 (+2.61%) As of 07:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PLUR vs. CYBN, VYGR, IMAB, ACOG, LFVN, DERM, IPHA, ENTA, SPRO, and NVCTShould you be buying Pluri stock or one of its competitors? The main competitors of Pluri include Cybin (CYBN), Voyager Therapeutics (VYGR), I-Mab (IMAB), Alpha Cognition (ACOG), Lifevantage (LFVN), Journey Medical (DERM), Innate Pharma (IPHA), Enanta Pharmaceuticals (ENTA), Spero Therapeutics (SPRO), and Nuvectis Pharma (NVCT). These companies are all part of the "pharmaceutical products" industry. Pluri vs. Its Competitors Cybin Voyager Therapeutics I-Mab Alpha Cognition Lifevantage Journey Medical Innate Pharma Enanta Pharmaceuticals Spero Therapeutics Nuvectis Pharma Cybin (NYSE:CYBN) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation. Which has better valuation and earnings, CYBN or PLUR? Pluri has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCybinN/AN/A-$57.88M-$3.88-1.92Pluri$330K119.48-$20.89M-$5.53-0.91 Is CYBN or PLUR more profitable? Cybin has a net margin of 0.00% compared to Pluri's net margin of -2,563.29%. Cybin's return on equity of -37.58% beat Pluri's return on equity.Company Net Margins Return on Equity Return on Assets CybinN/A -37.58% -36.59% Pluri -2,563.29%-4,191.91%-85.40% Does the media favor CYBN or PLUR? In the previous week, Pluri had 1 more articles in the media than Cybin. MarketBeat recorded 1 mentions for Pluri and 0 mentions for Cybin. Pluri's average media sentiment score of 0.93 beat Cybin's score of -0.18 indicating that Pluri is being referred to more favorably in the news media. Company Overall Sentiment Cybin Neutral Pluri Positive Which has more volatility and risk, CYBN or PLUR? Cybin has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Comparatively, Pluri has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Do insiders & institutionals hold more shares of CYBN or PLUR? 17.9% of Cybin shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 15.0% of Cybin shares are held by company insiders. Comparatively, 25.9% of Pluri shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts rate CYBN or PLUR? Cybin currently has a consensus price target of $85.00, suggesting a potential upside of 1,039.41%. Pluri has a consensus price target of $12.00, suggesting a potential upside of 139.52%. Given Cybin's stronger consensus rating and higher probable upside, analysts clearly believe Cybin is more favorable than Pluri.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cybin 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Pluri 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCybin beats Pluri on 9 of the 16 factors compared between the two stocks. Get Pluri News Delivered to You Automatically Sign up to receive the latest news and ratings for PLUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLUR vs. The Competition Export to ExcelMetricPluriMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.99M$2.96B$5.61B$9.29BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-0.9120.2228.5419.58Price / Sales119.48299.17429.2495.01Price / CashN/A43.1536.0257.93Price / Book5.017.568.145.54Net Income-$20.89M-$55.11M$3.24B$257.73M7 Day Performance-9.07%3.81%0.18%-0.08%1 Month Performance17.88%11.60%5.96%8.09%1 Year Performance-14.36%-2.11%26.24%13.02% Pluri Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLURPluri3.2875 of 5 stars$5.01-1.4%$12.00+139.5%-6.4%$39.99M$330K-0.91150Gap DownHigh Trading VolumeCYBNCybin2.4763 of 5 stars$7.70-2.2%$86.00+1,017.5%N/A$176.13MN/A-1.7550VYGRVoyager Therapeutics3.8881 of 5 stars$3.15+3.6%$13.39+325.1%-65.6%$173.82M$80M-2.15100IMABI-Mab2.8477 of 5 stars$2.13+1.7%$6.00+182.4%+28.8%$173.53M$3.89M0.00380Gap DownACOGAlpha Cognition1.727 of 5 stars$10.75-4.4%$20.00+86.0%N/A$172.22MN/A-8.96N/APositive NewsGap UpLFVNLifevantage4.2759 of 5 stars$13.43-1.2%$30.50+127.1%+102.6%$169.02M$200.16M19.46260News CoveragePositive NewsDERMJourney Medical2.4054 of 5 stars$7.23+1.8%$9.50+31.4%+19.9%$165.55M$56.13M-18.2290Positive NewsIPHAInnate Pharma2.6155 of 5 stars$1.79-1.6%$11.00+514.5%-16.5%$165.00M$21.77M0.00220ENTAEnanta Pharmaceuticals3.9272 of 5 stars$7.77-1.5%$18.00+131.7%-60.2%$164.26M$67.64M-1.69160News CoverageSPROSpero Therapeutics3.9053 of 5 stars$2.94+1.2%$5.00+70.4%+72.3%$164.10M$47.98M-2.29150NVCTNuvectis Pharma3.3056 of 5 stars$7.82-0.4%$17.00+117.5%+24.5%$163.36MN/A-6.928Positive News Related Companies and Tools Related Companies Cybin Competitors Voyager Therapeutics Competitors I-Mab Competitors Alpha Cognition Competitors Lifevantage Competitors Journey Medical Competitors Innate Pharma Competitors Enanta Pharmaceuticals Competitors Spero Therapeutics Competitors Nuvectis Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLUR) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pluri Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pluri With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.